Potential for developing purinergic drugs for gastrointestinal diseases

Inflammatory Bowel Diseases

Volumn 20, Issue 7, 2014, Pages 1259-1287

  Ochoa Cortes, Fernando ^a   Liñán Rico, Andromeda ^a   Jacobson, Kenneth A ^b   Christofi, Fievos L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

A3 receptors; Clinical trials; Endogenous adenosine; Inflammatory bowel disease; Inflammatory diarrhea; Irritable bowel syndrome; P2x ion channels; Purinergic drugs; Visceral pain

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE TRIPHOSPHATE; AF 219; AZD 9056; BIOLOGICAL MARKER; BVT 115959; CAFFEINE; CF 102; DIPYRIDAMOLE; GSK 1482160; GW 493838; IBEROGAST; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PURINERGIC P2X RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC RECEPTOR; PURINERGIC RECEPTOR AFFECTING AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT;

CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOTOXEMIA; ENTEROPATHY; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY PAIN; IRRITABLE COLON; MEDICINAL CHEMISTRY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VISCERAL PAIN; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; FORECASTING; GASTROINTESTINAL DISEASES; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; NEEDS ASSESSMENT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FORECASTING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; NEEDS ASSESSMENT; PURINERGIC AGENTS;

EID: 84905511570     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000047     Document Type: Review

References (241)

1. Burnstock G. Purinergic nerves. Pharmacol Rev. 1972;24:509-581.
2. Durnin L, Hwang SJ, Ward SM, et al. Adenosine 5'-diphosphate-ribose is a neural regulator in primate and murine large intestine along with [beta]-NAD+. J Physiol. 2012;590:1921-1941.
3. Hwang SJ, Durnin L, Dwyer L, et al. b-Nicotinamide adenine dinucleotide is an enteric inhibitory neurotransmitter in human and nonhuman primate colons. Gastroenterology. 2011;140:608-617.e6.
4. Hwang SJ, Blair PJ, Durnin L, et al. P2Y1 purinoreceptors are fundamental to inhibitory motor control of murine colonic excitability and transit. J Physiol. 2012;590:1957-1972.
5. Gallego D, Gil V, Aleu J, et al. Pharmacological characterization of purinergic inhibitory neuromuscular transmission in the human colon. Neurogastroenterology Motil. 2011;23:792-e338.
6. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87:659-797.
7. Burnstock G. Purinergic signalling in the gastrointestinal tract and related organs in health and disease. Purinergic Signal. 2014;10:3-50.
8. Burnstock G. Purinergic receptors as future targets for treatment of functional GI disorders. Gut. 2008;57:1193-1194.
9. Peri LE, Sanders KM, MutafovaYambolieva VN. Differential expression of genes related to purinergic signaling in smooth muscle cells, PDGFR [alpha]-positive cells, and interstitial cells of Cajal in the murine colon. Neurogastroenterology Motil. 2013;25:e609-e620.
10. Christofi FL. Purinergic receptors and gastrointestinal secretomotor function. Purinergic Signal. 2008;4:213-236.
11. Antonioli L, Fornai M, Colucci R, et al. Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:566-574.
12. Antonioli L, Fornai M, Colucci R, et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther. 2008;120:233-253.
13. Burnstock G. Targeting the visceral purinergic system for pain control. Curr Opin Pharmacol. 2012;12:80-86.
14. Roberts JA, Lukewich MK, Sharkey KA, et al. The roles of purinergic signaling during gastrointestinal inflammation. Curr Opin Pharmacol. 2012;12:659-666.
15. Jacobson KA, Jayasekara MP, Costanzi S. Molecular structure of P2Y receptors: mutagenesis, modeling, and chemical probes. Wiley Interdiscip Rev Membr Transp Signal. 2012;1:WMTS68.
16. North RA, Jarvis MF. P2X receptors as drug targets. Mol Pharmacol. 2013;83:759-769.
17. IUPHAR/BPS. Guide to Pharmacology. Available at: http://www. guidetopharmacology.org/Accessed April 8, 2014.
18. Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-116.
19. Haas SL, Ruether A, Singer MV, et al. Functional P2X7 receptor polymorphisms (His155Tyr, Arg307Gln, Glu496Ala) in patients with Crohn's disease. Scand J Immunol. 2007;65:166-170.
20. Fuller SJ, Stokes L, Skarratt KK, et al. Genetics of the P2X7 receptor and human disease. Purinergic Signal. 2009;5:257-262.
21. Parvathenani LK, Tertyshnikova S, Greco CR, et al. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem. 2003;278:13309-13317.
22. Barden N, Harvey M, Gagné B, et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24. 31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141:374-382.
23. Elliott JI, Higgins CF. Major histocompatibility complex class I shedding and programmed cell death stimulated through the proinflammatory P2X7 receptor: a candidate susceptibility gene for NOD diabetes. Diabetes. 2004;53:2012-2017.
24. Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
25. Fletcher JM, Lonergan R, Costelloe L, et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009;183:7602-7610.
26. Friedman DJ, Kunzli BM, A-Rahim YI, et al. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A. 2009;106:16788-16793.
27. Mabley J, Soriano F, Pacher P, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol. 2003;466:323-329.
28. Guzman J, Yu JG, Suntres Z, et al. ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm Bowel Dis. 2006;12:766-789.
29. Ren T, Grants I, Alhaj M, et al. Impact of disrupting adenosine A3 receptors (A3-/-AR) on colonic motility or progression of colitis in the mouse. Inflamm Bowel Dis. 2011;17:1698-1713.
30. Butler M, Sanmugalingam D, Burton VJ, et al. Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo. Eur J Immunol. 2012;42:3358-3368.
31. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87:1658-1663.
32. Pedrosa E, Loren V, Cabre E, et al. Bacteria and spontaneous experimental colitis: immunological changes. Eur J Clin Invest. 2011;41:1047-1053.
33. Teng B, Ledent C, Mustafa SJ. Up-regulation of A2B adenosine receptor in A2A adenosine receptor knockout mouse coronary artery. J Mol Cell Cardiol. 2008;44:905-914.
34. Fishman P, Bar-Yehuda S, Liang BT, et al. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17:359-366.
35. David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012;26:361-367.
36. Silverman MH, Strand V, Markovits D, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol. 2008;35:41-48.
37. Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology. 2010;117:1287-1293.
38. Du L, Gao ZG, Nithipatikom K, et al. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A (3) adenosine receptor. J Pharmacol Exp Ther. 2012;340:210-217.
39. Chen Z, Janes K, Chen C, et al. Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J. 2012;26:1855-1865.
40. CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome. Available at: http://www.news-medical.net/news/20131230/ CF101-drug-fails-to-meet-primary-efficacy-endpoint-in-phase-III-study-for-Dry- Eye-Syndrome.aspx. Accessed April 8, 2014.
41. Van Troostenburg A, Clark E, Carey W, et al. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther. 2004;42:534-542.
42. Wagner R, Ngamsri K, Stark S, et al. Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol. 2010;299:L502-L512.
43. Fishman P, Bar-Yehuda S, Madi L, et al. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther. 2006;8:R33.
44. Schlotzer-Schrehardt U, Zenkel M, Hofmann-Rummelt C, et al. Functional significance of adenosine receptors in the eye and their dysregulation in pseudoexfoliation syndrome [in German]. Ophthalmologe. 2005;102:1074-1080, 1082.
45. Ochaion A, Bar-Yehuda S, Cohen S, et al. The anti-inflammatory target A (3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol. 2009;258:115-122.
46. Madi L, Cohen S, Ochayin A, et al. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol. 2007;34:20-26.
47. Rybaczyk L, Rozmiarek A, Circle K, et al. New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC. Inflamm Bowel Dis. 2009;15:971-984.
48. Fischer D, Van der Weyden M, Snyderman R, et al. A role for adenosine deaminase in human monocyte maturation. J Clin Invest. 1976;58:399.
49. Antonioli L, Fornai M, Colucci R, et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther. 2007;322:435-442.
50. Maor I, Rainis T, Lanir A, et al. Adenosine deaminase activity in patients with Crohn's disease: distinction between active and nonactive disease. Eur J Gastroenterol Hepatol. 2011;23:598-602.
51. Cesaro A, Brest P, Hofman V, et al. Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. Am J Physiol Gastrointest Liver Physiol. 2010;299:G32-G42.
52. Kunzli BM, Berberat PO, Dwyer K, et al. Variable impact of CD39 in experimental murine colitis. Dig Dis Sci. 2011;56:1393-1403.
53. Grbic DM, Degagne E, Larrivee JF, et al. P2Y6 receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells. Inflamm Bowel Dis. 2012;18:1456-1469.
54. Kurashima Y, Amiya T, Nochi T, et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun. 2012;3:1034.
55. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med. 2012;367:2322-2333.
56. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247-264.
57. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res. 2010;316:1284-1288.
58. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov. 2013;12:265-286.
59. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxiainducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098-1106.
60. Hart ML, Gorzolla IC, Schittenhelm J, et al. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol. 2010;184:4017-4024.
61. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993-1002.
62. Rahimian R, Fakhfouri G, Daneshmand A, et al. Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBSinduced colitis in rats. Eur J Pharmacol. 2010;649:376-381.
63. Gao N, Hu HZ, Liu S, et al. Stimulation of adenosine A1 and A2A receptors by AMP in the submucosal plexus of guinea pig small intestine. Am J Physiol Gastrointest Liver Physiol. 2007;292:G492-G500.
64. Louis NA, Robinson AM, MacManus CF, et al. Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol. 2008;180:4246-4255.
65. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257-1265.
66. Strohmeier GR, Lencer WI, Patapoff TW, et al. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest. 1997;99:2588-2601.
67. Naganuma M, Wiznerowicz EB, Lappas CM, et al. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol. 2006;177:2765-2769.
68. Frick JS, MacManus CF, Scully M, et al. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol. 2009;182:4957-4964.
69. Aherne CM, Collins CB, Masterson JC, et al. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut. 2012;61:695-705.
70. Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkB. Proc Natl Acad Sci U S A. 1999;96:6377-6381.
71. Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;101:295.
72. Linden J. Cell biology. Purinergic chemotaxis. Science. 2006;314:1689-1690.
73. Gulbransen BD, Bashashati M, Hirota SA, et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med. 2012;18:600-604.
74. Souza VdoC, Schlemmer KB, Noal CB, et al. E-NTPDase and E-ADA activities are altered in lymphocytes of patients with indeterminate form of Chagas' disease. Parasitol Int. 2012.
75. Neshat S, deVries M, Barajas-Espinosa AR, et al. Loss of purinergic vascular regulation in the colon during colitis is associated with upregulation of CD39. Am J Physiol Gastrointest Liver Physiol. 2009;296:G399-G405.
76. Montesinos MC, Takedachi M, Thompson LF, et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-50-nucleotidase: findings in a study of ecto-50-nucleotidase gene-deficient mice. Arthritis Rheum. 2007;56:1440-1445.
77. Csóka B, Németh ZH, Virág L, et al. A2A adenosine receptors and C/EBPb are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood. 2007;110:2685-2695.
78. Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res. 1998;47:351-354.
79. Noji T, Takayama M, Mizutani M, et al. KF24345, an adenosine uptake inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor-a production and leukopenia via endogenous adenosine in mice. J Pharmacol Exp Ther. 2002;300:200-205.
80. van Eijk LT, Dorresteijn MJ, Smits P, et al. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 2007;35:1464-1469.
81. Riksen NP, Oyen WJ, Ramakers BP, et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther. 2005;78:52-59.
82. Ramakers BP, Riksen NP, Stal TH, et al. Dipyridamole augments the antiinflammatory response during human endotoxemia. Crit Care. 2011;15:R289.
83. Poturoglu S, Kaymakoglu S, Gurel Polat N, et al. A new agent for tumour necrosis factor-alpha inhibition. Scand J Clin Lab Invest. 2009;69:696-702.
84. Le Vraux V, Chen Y, Masson I, et al. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci. 1993;52:1917-1924.
85. Chello M, Mastroroberto P, Malta E, et al. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann Thorac Surg. 1999;67:1277-1282.
86. Jenner P, Mori A, Hauser R, et al. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord. 2009;15:406-413.
87. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10:221-229.
88. Teerlink JR, Iragui VJ, Mohr JP, et al. The safety of an adenosine A (1) - receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012;35:233-244.
89. Yang J, Björklund O, Lindström-Törnqvist K, et al. Mice heterozygous for both A1 and A2A adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol. 2009;106:631-639.
90. Fredholm BB, Bättig K, Holmén J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-133.
91. Greig E, Boot-Handford R, Mani V, et al. Decreased expression of apical Na channels and basolateral Na+, K +-ATPase in ulcerative colitis. J Pathol. 2004;204:84-92.
92. Amasheh S, Barmeyer C, Koch CS, et al. Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis. Gastroenterology. 2004;126:1711-1720.
93. Zeissig S, Bergann T, Fromm A, et al. Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease. Gastroenterology. 2008;134:1436-1447.
94. Sandle GI. Infective and inflammatory diarrhoea: mechanisms and opportunities for novel therapies. Curr Opin Pharmacol. 2011;11:634-639.
95. Haskó G, Csóka B, Németh ZH, et al. A 2B adenosine receptors in immunity and inflammation. Trends Immunol. 2009;30:263-270.
96. Kolachala V, Ruble B, Vijay-Kumar M, et al. Blockade of adenosine A2B receptors ameliorates murine colitis. Br J Pharmacol. 2008;155:127-137.
97. Strohmeier GR, Reppert SM, Lencer WI, et al. The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem. 1995;270:2387-2394.
98. Kolachala VL, Vijay-Kumar M, Dalmasso G, et al. A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology. 2008;135:861-870.
99. Sitaraman SV, Merlin D, Wang L, et al. Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest. 2001;107:861-869.
100. Kolachala V, Asamoah V, Wang L, et al. TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis. Cell Mol Life Sci. 2005;62:2647-2657.
101. Cooke HJCF. Chapter 27: enteric neural regulation of mucosal secretion. In: Jhonson LR, ed. Physiology of the Gastrointestinal Tract. 4th ed. New York: Academic Press; 2006:737-762.
102. Fang X, Hu H, Gao N, et al. Neurogenic secretion mediated by the purinergic P2Y1 receptor in guinea-pig small intestine. Eur J Pharmacol. 2006;536:113-122.
103. Lundgren O. Enteric nerves and diarrhoea. Pharmacol Toxicol. 2002;90:109-120.
104. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58:196-201.
105. Matkowskyj KA, Nathaniel R, Prasad R, et al. Galanin contributes to the excess colonic fluid secretion observed in dextran sulfate sodium murine colitis. Inflamm Bowel Dis. 2004;10:408-416.
106. Seidler U, Lenzen H, Cinar A, et al. Molecular mechanisms of disturbed electrolyte transport in intestinal inflammation. Ann N Y Acad Sci. 2006;1072:262-275.
107. Wunderlich JE, Needleman BJ, Chen Z, et al. Dual purinergic synaptic transmission in the human enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2008;294:G554-G566.
108. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657-1664.
109. Christofi FL. Unlocking mysteries of gut sensory transmission: is adenosine the key? News Physiol Sci. 2001;16:201-207.
110. Cressman VL, Lazarowski E, Homolya L, et al. Effect of loss of P2Y (2) receptor gene expression on nucleotide regulation of murine epithelial Cl (-) transport. J Biol Chem. 1999;274:26461-26468.
111. Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum. 2007;50:376-388.
112. Kraneveld AD, Rijnierse A, Nijkamp FP, et al. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol. 2008;585:361-374.
113. Linden DR, Foley KF, McQuoid C, et al. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil. 2005;17:565-574.
114. Burnstock G. P2X receptors in the gut. Wiley Interdiscip Rev Membr Transp Signal. 2012;1:269-279.
115. Rodrigues RJ, Almeida T, Richardson PJ, et al. Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J Neurosci. 2005;25:6286-6295.
116. Christofi FL, Wunderlich J, Yu JG, et al. Mechanically evoked reflex electrogenic chloride secretion in rat distal colon is triggered by endogenous nucleotides acting at P2Y1, P2Y2, and P2Y4 receptors. J Comp Neurol. 2004;469:16-36.
117. Cooke HJ, Wunderlich J, Christofi FL. "The force be with you": ATP in gut mechanosensory transduction. News Physiol Sci. 2003;18:43-49.
118. Cooke HJ, Xue J, Yu JG, et al. Mechanical stimulation releases nucleotides that activate P2Y1 receptors to trigger neural reflex chloride secretion in guinea pig distal colon. J Comp Neurol. 2004;469:1-15.
119. Xia Y, Hu HZ, Liu S, et al. Clostridium difficile toxin A excites enteric neurones and suppresses sympathetic neurotransmission in the guinea pig. Gut. 2000;46:481-486.
120. Wunderlich JE, Ren T, Needleman B, et al. Novel purinergic P1, P2X and P2Y receptor signaling targets in the human enteric nervous system and glia. Gastroenterology. 2009;136:A-3
121. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397-414.
122. Christofi FL, Kim M, Wunderlich JE, et al. Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell model. Gastroenterology. 2004;127:188-202.
123. Haugen M, Dammen R, Svejda B, et al. Differential signal pathway activation and 5-HT function: the role of gut enterochromaffin cells as oxygen sensors. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1164-G1173.
124. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology. 2009;111:904.
125. Broad RM, Cook MA. Inhibition of neurotransmitter release from enteric nerve endings by 2-[p-(carboxyethyl)-phenethylamino]-5'- Nethylcarboxamidoadenosine (CGS-21680) and related adenosine analogs: lack of simple competition by antagonists. J Pharmacol Exp Ther. 1993;266:634-641.
126. Semenza GL. HIF-1, O (2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001;107:1-3.
127. Matheus N, Mendoza C, Iceta R, et al. Regulation of serotonin transporter activity by adenosine in intestinal epithelial cells. Biochem Pharmacol. 2009;78:1198-1204.
128. Damen R, Haugen M, Svejda B, et al. The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel disease. PLoS One. 2013;8:e62607.
129. Linan Rico A, Wunderlich JE, Grants IS, et al. Purinergic autocrine regulation of mechanosensitivity and serotonin release in a human EC model: ATP-gated P2X3 channels in EC are downregulated in ulcerative colitis. Inflamm Bowel Dis. 2013;19:2366-2379.
130. Kobie JJ, Shah PR, Yang L, et al. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 50-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780-6786.
131. Odashima M, Bamias G, Rivera-Nieves J, et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology. 2005;129:26-33.
132. Alam MS, Kurtz CC, Wilson JM, et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol. 2009;2:232-242.
133. Orrú M, Quiroz C, Guitart X, et al. Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology. 2011;61:967-974.
134. Armentero MT, Pinna A, Ferré S, et al. Past, present and future of A (2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther. 2011;132:280-299.
135. Moriyama K, Sitkovsky MV. Adenosine A2A receptor is involved in cell surface expression of A2B receptor. J Biol Chem. 2010;285:39271-39288.
136. Canals M, Marcellino D, Fanelli F, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem. 2003;278:46741-46749.
137. Ciruela F, Casadó V, Rodrigues RJ, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci. 2006;26:2080-2087.
138. Ferré S, Karcz-Kubicha M, Hope BT, et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A. 2002;99:11940-11945.
139. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
140. Ivison SM, Himmel ME, Mayer M, et al. The stress signal extracellular ATP modulates antiflagellin immune responses in intestinal epithelial cells. Inflamm Bowel Dis. 2011;17:319-333.
141. Souza CO, Santoro GF, Figliuolo VR, et al. Extracellular ATP induces cell death in human intestinal epithelial cells. Biochim Biophys Acta. 2012;1820:1867-1878.
142. Grbic DM, Degagne E, Langlois C, et al. Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. J Immunol. 2008;180:2659-2668.
143. Degagne E, Turgeon N, Moore-Gagne J, et al. P2Y (2) receptor expression is regulated by C/EBPbeta during inflammation in intestinal epithelial cells. FEBS J. 2012;279:2957-2965.
144. Antonioli L, Fornai M, Colucci R, et al. Control of enteric neuromuscular functions by purinergic A (3) receptors in normal rat distal colon and experimental bowel inflammation. Br J Pharmacol. 2010;161:856-871.
145. Bozarov A, Wang YZ, Yu JG, et al. Activation of adenosine low-affinity A3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine. Am J Physiol Gastrointest Liver Physiol. 2009;297:G1147-G1162.
146. Breunig E, Michel K, Zeller F, et al. Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol. 2007;583:731-742.
147. Chandrasekharan BP, Kolachala VL, Dalmasso G, et al. Adenosine 2B receptors (A (2B) AR) on enteric neurons regulate murine distal colonic motility. FASEB J. 2009;23:2727-2734.
148. Antonioli L, Fornai M, Colucci R, et al. Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. Eur J Pharmacol. 2011;650:639-649.
149. Fornai M, Antonioli L, Colucci R, et al. A1 and A2a receptors mediate inhibitory effects of adenosine on the motor activity of human colon. Neurogastroenterol Motil. 2009;21:451-466.
150. Cooke HJ, Wang Y, Liu CY, et al. Activation of neuronal adenosine A1 receptors suppresses secretory reflexes in the guinea pig colon. Am J Physiol. 1999;276:G451-G462.
151. Kadowaki M, Nagakura Y, Tokita K, et al. Adenosine A1 receptor blockade reverses experimental postoperative ileus in rat colon. Eur J Pharmacol. 2003;458:197-200.
152. Wang L, Yao H, Yang Y, et al. Enhanced purinergic pathway occurs in postoperative ileus: reversal by orphanin FQ. Gastroenterology. 2004;126:A11.
153. Strong DS, Cornbrooks CF, Roberts JA, et al. Purinergic neuromuscular transmission is selectively attenuated in ulcerated regions of inflamed guinea pig distal colon. J Physiol. 2010;588:847-859.
154. Cosimelli B, Taliani S, Greco G. Derivatives of benzimidazol-2- ylquinoline and benzimidazol-2-ylisoquinoline as selective A1 adenosine receptor antagonists with stimulant activity on human colon motility. ChemMedChem. 2011;6:1909-1918.
155. Auli M, Martinez E, Gallego D, et al. Effects of excitatory and inhibitory neurotransmission on motor patterns of human sigmoid colon in vitro. Br J Pharmacol. 2008;155:1043-1055.
156. Wang G, Wang X, Hu H, et al. Inhibitory neuromuscular transmission mediated by the P2Y1 purinergic receptor in guinea pig small intestine. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1483-G1489.
157. Gulbransen BD, Sharkey KA. Purinergic neuron-to-glia signaling in the enteric nervous system. Gastroenterology. 2009;136:1349-1358.
158. Burnstock G. Targeting the visceral purinergic system for pain control. Curr Opin Pharmacol. 2012;12:80-86.
159. Fan J, Yu LH, Zhang Y, et al. Estrogen altered visceromotor reflex and P2X (3) mRNA expression in a rat model of colitis. Steroids. 2009;74:956-962.
160. Yiangou Y, Facer P, Baecker PA, et al. ATP-gated ion channel P2X (3) is increased in human inflammatory bowel disease. Neurogastroenterol Motil. 2001;13:365-369.
161. Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012;8:3-26.
162. Rong W, Keating C, Sun B, et al. Purinergic contribution to small intestinal afferent hypersensitivity in a murine model of postinfectious bowel disease. Neurogastroenterology Motil. 2009;21:665-671, e32.
163. Shinoda M, Feng B, Gebhart G. Peripheral and central P2X3 receptor contributions to colon mechanosensitivity and hypersensitivity in the mouse. Gastroenterology. 2009;137:2096-2104.
164. Xu GY, Shenoy M, Winston JH, et al. P2X receptor-mediated visceral hyperalgesia in a rat model of chronic visceral hypersensitivity. Gut. 2008;57:1230-1237.
165. Altomare A, Guarino MP, Cicala M, et al. Gastrointestinal sensitivity and gastroesophageal reflux disease. Ann N Y Acad Sci. 2013;1300:80-95.
166. Cockayne DA, Hamilton SG, Zhu Q, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407:1011-1015.
167. Vlaskovska M, Kasakov L, Rong W, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001;21:5670-5677.
168. Dang K, Lamb K, Cohen M, et al. Cyclophosphamide-induced bladder inflammation sensitizes and enhances P2X receptor function in rat bladder sensory neurons. J Neurophysiol. 2008;99:49-59.
169. Fukuda K, Hayashida M, Fukunaga A, et al. Pain-relieving effects of intravenous ATP in chronic intractable orofacial pain: an open-label study. J Anesth. 2007;21:24-30.
170. Handa T, Fukuda K, Hayashida M, et al. Effects of intravenous adenosine 50-triphosphate on intraoperative hemodynamics and postoperative pain in patients undergoing major orofacial surgery: a double-blind placebo-controlled study. J Anesth. 2009;23:315-322.
171. Habib AS, Minkowitz H, Osborn T, et al. Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. Anesthesiology. 2008;109:1085-1091.
172. Gunosewoyo H, Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat. 2010;20:625-646.
173. Gever JR, Soto R, Henningsen RA, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010;160:1387-1398.
174. Ballini E, Virginio C, Medhurst S, et al. Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model. Br J Pharmacol. 2011;163:1315-1325.
175. Beneng K, Yilmaz Z, Yiangou Y, et al. Sensory purinergic receptor P2X3 is elevated in burning mouth syndrome. Int J Oral Maxillofac Surg. 2010;39:815-819.
176. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs. 2011;20:897-915.
177. Harrison C. Patent watch. Nat Rev Drug Discov. 2008;7:553.
178. Malin SA, Molliver DC. Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Mol Pain. 2010;6:21. 8069-6-21.
179. Fernando SL, Saunders BM, Sluyter R, et al. A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med. 2007;175:360-366.
180. Niño-Moreno P, Portales-Pérez D, Hernández-Castro B, et al. P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with pulmonary tuberculosis. Clin Exp Immunol. 2007;148:469-477.
181. Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386-396.
182. McGaraughty S, Chu K, Namovic M, et al. P2X7-related modulation of pathological nociception in rats. Neuroscience. 2007;146:1817-1828.
183. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440.
184. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176:3877-3883.
185. Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224, 535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39:720-727.
186. von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon forpatients with functional dyspepsia: results of a multicenter, placebocontrolled double-blind study. Am J Gastroenterol. 2007;102:1268-1275.
187. Madisch A, Holtmann G, Mayr G, et al. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebocontrolled, multicenter trial. Digestion. 2004;69:45-52.
188. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19:271-279.
189. Michael S, Abdel-Aziz H, Weiser D, et al. Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast (R)) in rat small intestinal preparations. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:411-421.
190. Soares-Bezerra RJ, Calheiros AS, da Silva Ferreira NC, et al. Natural products as a source for new anti-inflammatory and analgesic compounds through the inhibition of purinergic P2X receptors. Pharmaceuticals (Basel). 2013;6:650-658.
191. Zhang X, Chen H, Li Z, et al. Analgesic effect of paeoniflorin in rats with neonatal maternal separation-induced visceral hyperalgesia is mediated through adenosine A1 receptor by inhibiting the extracellular signalregulated protein kinase (ERK) pathway. Pharmacol Biochem Behav. 2009;94:88-97.
192. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20:463-465.
193. Smecuol E, Bai J, Sugai E, et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut. 2001;49:650-655.
194. Whittle BJ. Mechanisms underlying intestinal injury induced by antiinflammatory COX inhibitors. Eur J Pharmacol. 2004;500:427-439.
195. Bours MJ, Troost FJ, Brummer RJ, et al. Local effect of adenosine 5'-triphosphate on indomethacin-induced permeability changes in the human small intestine. Eur J Gastroenterol Hepatol. 2007;19:245-250.
196. Fukuda Y, Bamba H, Okui M, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion. 2001;63:93-96.
197. Murphy M, Eastham E, Nelson R, et al. Intestinal permeability in Crohn's disease. Arch Dis Child. 1989;64:321-325.
198. Welcker K, Martin A, Kolle P, et al. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res. 2004;9:456-460.
199. Arnott I, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol. 2000;35:1163-1169.
200. D'Incà R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol. 1999;94:2956-2960.
201. DeMeo MT, Mutlu EA, Keshavarzian A, et al. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol. 2002;34:385-396.
202. Barbara G, Cremon C, De Giorgio R, et al. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep. 2011;13:308-315.
203. Wagner MC. The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART. Curr HIV Res. 2011;9:209-222.
204. Voss U, Turesson MF, Robaye B, et al. The enteric nervous system of P2Y13 receptor null mice is resistant against high-fat-diet- and palmiticacidinduced neuronal loss. Purinergic Signal. 2014.
205. Espada S, Ortega F, Molina-Jijon E, et al. The purinergic P2Y (13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radic Biol Med. 2010;49:416-426.
206. Adjei A, Morioka T, Ameho C, et al. Nucleoside-nucleotide free diet protects rat colonic mucosa from damage induced by trinitrobenzene sulphonic acid. Gut. 1996;39:428-433.
207. Adjei AA, Ameho CK, Harrison EK, et al. Nucleoside-nucleotide-free diet suppresses cytokine production and contact sensitivity responses in rats with trinitrobenzene sulphonic acid-induced colitis. Am J Med Sci. 1997;314:89-96.
208. Somers GR, Hammet FM, Trute L, et al. Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease. Lab Invest. 1998;78:1375-1383.
209. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808:1290-1308.
210. Keating C, Pelegrin P, Martínez CM, et al. P2X7 receptor-dependent intestinal afferent hypersensitivity in a mouse model of postinfectious irritable bowel syndrome. J Immunol. 2011;187:1467-1474.
211. Bynoe MS, Waickman AT, Mahamed DA, et al. CD73 is critical for the resolution of murine colonic inflammation. J Biomed Biotechnol. 2012;2012:260983.
212. Gil V, Martinez-Cutillas M, Mane N, et al. P2Y (1) knockout mice lack purinergic neuromuscular transmission in the antrum and cecum. Neurogastroenterol Motil. 2013;25:e170-e182.
213. Shinoda M, La JH, Bielefeldt K, et al. Altered purinergic signaling in colorectal dorsal root ganglion neurons contributes to colorectal hypersensitivity. J Neurophysiol. 2010;104:3113-3123.
214. Guo X, Chen J, Lu Y, et al. Electroacupuncture at He-Mu points reduces P2X4 receptor expression in visceral hypersensitivity. Neural Regen Res. 2013;8:2069-2077.
215. Migita K, Moriyama T, Koguchi M, et al. Modulation of P2X receptors in dorsal root ganglion neurons of streptozotocin-induced diabetic neuropathy. Neurosci Lett. 2009;452:200-203.
216. Xu GY, Li G, Liu N, et al. Mechanisms underlying purinergic P2X3 receptor-mediated mechanical allodynia induced in diabetic rats. Mol Pain. 2011;7:60. 8069-7-60.
217. Shi L, Zhang HH, Hu J, et al. Purinergic P2X receptors and diabetic neuropathic pain. Sheng Li Xue Bao. 2012;64:531-542.
218. O'Donnell AM, Puri P. Deficiency of purinergic P2Y receptors in aganglionic intestine in Hirschsprung's disease. Pediatr Surg Int. 2008;24:77-80.
219. De Man JG, Seerden TC, De Winter BY, et al. Alteration of the purinergic modulation of enteric neurotransmission in the mouse ileum during chronic intestinal inflammation. Br J Pharmacol. 2003;139:172-184.
220. Degagne E, Grbic DM, Dupuis AA, et al. P2Y2 receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells. J Immunol. 2009;183:4521-4529.
221. Roberts JA, Durnin L, Sharkey KA, et al. Oxidative stress disrupts purinergic neuromuscular transmission in the inflamed colon. J Physiol. 2013;591:3725-3737.
222. Antonioli L, Fornai M, Colucci R, et al. A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. Inflamm Bowel Dis. 2006;12:117-122.
223. Lomax AE, Mawe GM, Sharkey KA. Synaptic facilitation and enhanced neuronal excitability in the submucosal plexus during experimental colitis in guineapig. J Physiol. 2005;564:863-875.
224. Pretorius J, Malan SF, Castagnoli N, et al. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E, E)-8-(4-phenylbutadien-1-yl) caffeine analogues. Bioorg Med Chem. 2008;16:8676-8684.
225. Mitrovic V, Seferovic P, Dodic S, et al. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circ Heart Fail. 2009;2:523-531.
226. Pang PS, Mehra M, Maggioni AP, et al. Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. Am Heart J. 2011;161:1012-1023. e3.
227. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645-658.
228. Prenner BM, Bukofzer S, Behm S, et al. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012;19:681-692.
229. Moeller FG, Steinberg JL, Lane SD, et al. Increased orbitofrontal brain activation after administration of a selective adenosine A (2A) antagonist in Cocaine dependent subjects. Front Psychiatry. 2012;3:44.
230. Jakobsen O, Naesheim T, Aas KN, et al. Adenosine instead of supranormal potassium in cardioplegia: it is safe, efficient, and reduces the incidence of postoperative atrial fibrillation. A randomized clinical trial. J Thorac Cardiovasc Surg. 2013;145:812-818.
231. El Tahan MR. Effects of aminophylline on cognitive recovery after sevoflurane anesthesia. J Anesth. 2011;25:648-656.
232. Available at: http://www.astrazenecaclinicaltrials.com/Submission/View? id=1884. Accessed April 10, 2014.
233. Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71:1630-1635.
234. Ali Z, Laurijssens B, Ostenfeld T, et al. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin Pharmacol. 2013;75:197-207.
235. Erlinge D, Gurbel PA, James S, et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol. 2013;62:577-583.
236. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917.
237. Spiel AO, Derhaschnig U, Schwameis M, et al. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci (Lond). 2012;123:591-600.
238. Jarvis MF, Burgard EC, McGaraughty S, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A. 2002;99:17179-17184.
239. McGaraughty S, Wismer CT, Zhu CZ, et al. Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br J Pharmacol. 2003;140:1381-1388.
240. Gessi S, Merighi S, Varani K, et al. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther. 2008;117:123-140.
241. Brown JB, Lee G, Grimm GR, et al. Therapeutic benefit of pentostatin in severe IL-102/2 Colitis. Inflamm Bowel Dis. 2008;14:880-887.